CAD treatment riliprubart may be given every 3 months: Study
Riliprubart (SAR445088), a potential successor to Enjaymo (sutimlimab-jome) as a cold agglutinin disease (CAD) treatment, may achieve therapeutic levels with every-three-month dosing at a fixed dose. That’s according to a study that used modeling tools to analyze available clinical trial data and propose an optimal dosing regimen for…